Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixarelimab in prurigo nodularis
NCT03816891Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2019
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of vixarelimab in prurigo nodularis (PN) (7 arms), sponsored by Genentech. Primary endpoint: Worst Itch-Numeric Rating Scale at 16 weeks. Started Mar 2019; status: completed.
02
Drugs
vixarelimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT03816891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816891.